<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283253</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00003161</org_study_id>
    <nct_id>NCT04283253</nct_id>
  </id_info>
  <brief_title>Predictors of Response in Chronic Stroke</brief_title>
  <acronym>SRT5</acronym>
  <official_title>Neurophysiological and Kinematic Predictors of Response in Chronic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Pittsburgh Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Pittsburgh Healthcare System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will validate a predictive model that uses demographics, functional status,
      neurophysiology, neuroanatomy, and other potential biomarkers to predict the likelihood of a
      clinically significant change in impairment at the end of a robot assisted therapy
      intervention.The study will include magnetic resonance imaging (MRI), transcranial magnetic
      stimulation (TMS), and an arm exercise program consisting of robot-assisted exercise combined
      with functional arm exercise called transition to task training (TTT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, a baseline neurological exam, medical records review, MRI of the
      brain, TMS, questionnaires, cognitive testing, robot evaluations, and arm function testing
      will occur. Baseline testing will occur in the first 4-6 weeks of participation including two
      separate sessions approximately 1 week a part to examine arm strength, range of motion, and
      ability to perform functional tasks, with one additional session if needed to verify
      stability between results. Additionally, one robot evaluation will be completed.

      The intervention phase consists of 12 weeks of robot and transition to task arm exercise
      training (TTT). Interventions will occur approximately 3 times per week for 12 weeks for a
      total of 36 visits. Additional time and visits will be allowed with visits occurring 4 times
      per week or up to 6 additional weeks (not to exceed 18 weeks) if scheduling conflicts arise.
      The intervention sessions will be one hour in duration.

      During the hour-long intervention, 45 minutes of robotic intervention will be followed by 15
      minutes of TTT. The training will be sequential with 12 sessions focused on the wrist,
      followed by 12 sessions on the shoulder-elbow and the final 12 sessions alternating between
      the wrist and elbow-shoulder.

      After the final training session, subjects will return after a 12 week retention period. At
      various time points during and after the intervention phase there will be additional arm
      function testing, robot evaluations, questionnaires, MRI and TMS sessions for re-assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">August 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One-arm, multiple baseline sequential, cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A change in the Fugl-Meyer Upper Extremity Assessment score</measure>
    <time_frame>Immediately following the 12-week intervention</time_frame>
    <description>The Fugl-Meyer is one of the primary outcome measures assessing change in arm use from baseline testing to mid-training after visits 12 and 24, and post-training after visit 36 and the 12 week retention period. It is a stroke-specific measure of impairment of the upper extremity that has been shown to be valid and reliable with high inter-rater and test-retest reliability. It provides a direct-observational assessment of volitional movement and motor impairment related to reflexes, sensation, and abnormal synergies. Each item on the FM is rated on a three-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully). The scale ranges from 0-66 with higher scores representing less motor impairment.</description>
  </primary_outcome>
  <other_outcome>
    <measure>A change in motor evoked potential during Transcranial Magnetic Stimulation of the motor cortex</measure>
    <time_frame>Immediately following the 12-week intervention</time_frame>
    <description>TMS stimulation of the motor cortex will be performed using MagStim 200 Magnetic Stimulators (MagStim Ltd., Wales, UK) to assess change in the motor evoked potential (MEP) of the arm muscles.</description>
  </other_outcome>
  <other_outcome>
    <measure>A change in brain connections assessed via MRI of the brain</measure>
    <time_frame>Immediately following the 12-week intervention</time_frame>
    <description>A detailed analysis of the MRI data will examine individual interregional connections to determine whether any of them are more sensitive to the intervention than others.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Stroke</condition>
  <condition>Brain Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Robot + TTT Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robot + TTT exercise</intervention_name>
    <description>The intervention will be completed 36 visits approximately 3x/week for 12-18 weeks. The training progression will be sequential with 12 visits completed on the wrist robot, followed by 12 visits on the shoulder-elbow robot and completing with 12 visits alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.</description>
    <arm_group_label>Robot + TTT Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically defined, unilateral, hemiparetic stroke with radiologic exclusion of other
             possible diagnosis

          -  Stroke onset at least 6 months before enrollment

          -  Present with Mild/Moderate to Severe arm dysfunction (based on Fugl-Meyer scores of 10
             to 45)

          -  Be medically stable to participate in the study

          -  Be English speaking

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Have a serious complicating medical illness that would preclude participation.

          -  Contractures or orthopedic problems limiting range of joint motion in the potential
             study arm

          -  Visual loss such that the subject would not be able to see the test patterns on the
             robot computer monitor

          -  Botulinum toxin to study arm within four months of study enrollment or if received
             during the study period

          -  Unable to comply with requirements of the study

          -  Participants with a history of a seizure will not be precluded from the study, but
             will not be enrolled in the TMS portions

          -  Participants with electromagnetic exclusions (metal implants in the cranium, implanted
             electronic devices etc.) will not be precluded from the study but will be excluded
             from the MRI and TMS portions

          -  Have a serious complicating medical illness that would preclude participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Wittenberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Boos, MS</last_name>
    <phone>4126484179</phone>
    <email>amy.boos@pitt.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George Wittenberg, PhD</last_name>
    <phone>4126484178</phone>
    <email>GEOWITT@PITT.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Boos, MS</last_name>
      <phone>412-648-4179</phone>
      <email>amy.boos@pitt.edu</email>
    </contact>
    <contact_backup>
      <last_name>George Wittenberg, PhD</last_name>
      <phone>4126484178</phone>
      <email>GEOWITT@PITT.EDU</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jim√©nez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 7;135(10):e146-e603. doi: 10.1161/CIR.0000000000000485. Epub 2017 Jan 25. Review. Erratum in: Circulation. 2017 Mar 7;135(10 ):e646. Circulation. 2017 Sep 5;136(10 ):e196.</citation>
    <PMID>28122885</PMID>
  </reference>
  <reference>
    <citation>Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev. 2018 Sep 3;9:CD006876. doi: 10.1002/14651858.CD006876.pub5. Review.</citation>
    <PMID>30175845</PMID>
  </reference>
  <reference>
    <citation>Stinear CM, Byblow WD, Ackerley SJ, Barber PA, Smith MC. Predicting Recovery Potential for Individual Stroke Patients Increases Rehabilitation Efficiency. Stroke. 2017 Apr;48(4):1011-1019. doi: 10.1161/STROKEAHA.116.015790. Epub 2017 Mar 9.</citation>
    <PMID>28280137</PMID>
  </reference>
  <reference>
    <citation>Connell LA, Smith MC, Byblow WD, Stinear CM. Implementing biomarkers to predict motor recovery after stroke. NeuroRehabilitation. 2018;43(1):41-50. doi: 10.3233/NRE-172395. Review.</citation>
    <PMID>30056436</PMID>
  </reference>
  <reference>
    <citation>Lang CE, Bland MD, Bailey RR, Schaefer SY, Birkenmeier RL. Assessment of upper extremity impairment, function, and activity after stroke: foundations for clinical decision making. J Hand Ther. 2013 Apr-Jun;26(2):104-14;quiz 115. doi: 10.1016/j.jht.2012.06.005. Epub 2012 Sep 10. Review.</citation>
    <PMID>22975740</PMID>
  </reference>
  <reference>
    <citation>Gauthier LV, Taub E, Mark VW, Perkins C, Uswatte G. Improvement after constraint-induced movement therapy is independent of infarct location in chronic stroke patients. Stroke. 2009 Jul;40(7):2468-72. doi: 10.1161/STROKEAHA.109.548347. Epub 2009 May 21.</citation>
    <PMID>19461024</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A de-identified, anonymized dataset will be created and shared. Where practicable, sharing should take place under a written agreement prohibiting the recipient from identifying or re-identifying (or taking steps to identify or reidentify) any individual whose data are included in the dataset. However, it is permissible for final datasets in machine-readable format to be submitted to and accessed from PubMed Central (and similar sites) provided that care is taken to ensure that the individuals cannot be re-identified using other publicly available information.
Datasets will be made available to the public following appropriate approvals for disclosure criteria.
Every effort will be made to protect personal privacy and the confidentiality of private information collected for research purposes. This particular dataset will be de-identified and the minimum amount of information necessary to achieve the objectives of the research proposed will be collected and shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

